For Novartis, oncology is a key strategic area, but it is still short of dominating the field. It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss ...

Signature is a new kind of clinical trial developed by US Novartis Oncology' says Novartis on the website. 'Instead of traveling far to see a doctor, the patient can stay locally and be treated by ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.

Novartis didn’t have the best experience with bispecifics in oncology. The company paid Xencor $150 million upfront in 2016 to co-develop two CD3 T-cell engaging bispecifics, only to have ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Legos joins the Big Pharma from Novartis, where he served as executive vice president and global head of oncology and hematology development. Before that, Legos held various leadership roles at GSK.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

The partnership focuses on radioligand therapy, cell therapy, and early-phase trials. Singapore General Hospital (SGH) and ...

Novartis operates as a single global operating segment. It is now concentrating on four core therapeutic areas — cardiovascular- renal-metabolic, immunology, neuroscience and oncology.